ArticleJournal of the American Chemical Society2025
Selective Iridium-Catalyzed Reductive Amination Inside Living Cells.
Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expanding the Organoiridium Catalyst Design Space Using Sulfur-Containing Bioisosteres.Inorganic chemistry · 2026Article
- Metal complexes in medicine: structural scaffoldsChemical science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Given that amino groups are ubiquitous in bioactive molecules, abiotic routes to incorporate them into cellular species offer new opportunities to study and manipulate living systems. In the present work, we report the first biocompatible method to prepare 1°, 2°, or 3° amines selectively starting from an aldehyde and nitrogen precursor through iridium-catalyzed reductive amination. To prevent overalkylation, we developed a nontoxic self-immolative agent comprising 4-(1-aminoethyl)phenol that can condense with carbonyl groups and undergo 1,6-elimination upon reduction to the desired 1° amines. The use of an electron-poor half-sandwich Ir catalyst favored the formation of amine over alcohol products. To synthesize 2° or 3° amines, the aldehydes were combined with the appropriate 1° or 2° amine, respectively, under our standard reaction conditions. Our method is sufficiently mild to perform on proteins, as demonstrated by the conversion of aldehyde-containing allysine residues in bovine serum albumin to lysine. Importantly, we showed that Ir-catalyzed reductive amination could be applied inside living cells, such as by generating the alkaloid phenethylamine or calcium-reducing drug cinacalcet to elicit different biological responses. The amines formed via intracellular reductive amination were quantified by high performance liquid chromatography, revealing that turnover numbers of up to ∼20 were achieved. This work is expected to enable greater versatility and precision in transforming a wide range of aldehyde-containing entities within living environments, further expanding our biosynthetic chemistry toolbox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.